Further examination by GSEA using the HSP70 inhibition signatures [27] revealed a robust disruption of HSP70 gene programs by ARVib and Nic treatment in Enza-resistant prostate cancer cells (Fig. 3E and Supplementary Fig. 4C). This evidence concerns the gene HSPA1A and Familial prostate cancer.